chevron_left
The impact of GLP-1RAs on bariatric surgery
Speakers
Glucagon-like peptide-1 (GLP-1) receptor agonists have recently witnessed a meteoric rise in popularity for obesity and weight loss. Studies have shown that GLP-1 receptor agonists can be effective for people with obesity, promoting sustained weight management and potentially reducing the risk of weight-related comorbidities.
The initial surge in the adoption of these drugs is anticipated to disrupt multiple areas of the medtech sector, with obesity interventions being one of the most directly impacted.
This webinar will provide insights into how GLP-1 receptor agonists are impacting bariatric surgery, including:
- Trends seen in obesity drug prescriptions versus bariatric surgery volumes
- Target patient groups for the two treatment options
- Correlations we’ve seen in bariatric surgery volumes and associated device sales so far
- Perspectives shared by bariatric surgeons and endocrinologists
Interested in learning more market insights or anything else?
